| Price | $35.55 |
| Year Range | $31.64 – $49.99 |
| Market Cap | $48.2B |
| PE Ratio | 89.5 |
| Industry | Medical & Dental Instruments |
What Is Medline’s AI Stock Analysis?
Medline’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Medline’s momentum in near-real time.
Medline (MDLN) has an AltIndex AI Score of 49/100, currently a Hold signal. The AI Score distills Medline's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Medline’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Medline — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving MDLN’s AI Score?
Fundamentals
Revenue for the last quarter was $7.69B. This is an increase of 4.53% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 11.60%, suggesting positive year-over-year growth. Net income for the last quarter was $60M. This represents a decrease of 53.49% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 81.98%, which may be a cause for concern. Ebitda for the last quarter was $659M. This represents a decrease of 3.23% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 21.73%, which may be a cause for concern. The current P/E ratio is 89.5. This may be considered high, potentially indicating overvaluation and a bearish outlook. In the last couple of months, there's been a couple of company insiders selling their stock, a potentially bearish signal.
See Medline’s earnings and insider transactions.
Technicals
Today's stock price is $35.55. This represents a decrease of 2.84% compared to a month ago, which may be concerning in the short-term. However, compared to a year ago, there is a decrease of 13.29%, which could be a cause for long-term concern. The trend is bullish. The current SMA10 is $35.26, which is higher than the previous SMA10 of $35.17. This indicates a potential upward trend in price movement. The RSI is 55.7, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
Medline has an estimated 607 open positions. This number is down by -12% in the last couple of months, indicating a company trying to improve its margins or cut costs. Not a great sign for a growing company. The business outlook among employees at Medline is neutral. Medline has an estimate of 1.5M visitors to their webpage. The number of visitors is up by 6% in the last couple of months, a bullish trend as this can indicate can increase in customers.
Explore Medline’s job postings, web traffic and app downloads.
Sentiment & social
The sentiment for the stock on various stock forums is very high, a positive sign.
Track Medline’s market sentiment.
Frequently Asked Questions: Medline AI Stock Analysis
Medline's AltIndex AI Score is 49/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Medline a Hold (49/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Medline — company overview, fundamentals, technicals and alternative data, with a recommendation. See the MDLN AI Score or sign up to read the full thesis.
